Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal
À propos du CIUSSS
Accueil Plan du site Courrier Portail Québec
Size of text

Guy Chouinard

Guy Chouinard, M.D., M. Sc. pharmacology
F.R.C.P.(C), F.A.P.A.

Fernand-Seguin Research Centre
Louis-H. Lafontaine Hospital
7401 Hochelaga St.
Montreal, QC,
Canada H1N 3M5
Phone : (514) 251-4015
Fax.: (514) 251-2617
Email : guy.chouinard@umontreal.ca

Research areas

Neuroscience (fundamental track)

Academic profile

Professor, Psychiatry Department, McGill University
Tenured Professor, Psychiatry Department, Université de Montréal
Director, Clinical Psychopharmacology Unit, Allan Memorial Institute, Psychiatry Department, McGill University
Psychiatrist and Pharmacology Clinician, Fernand-Seguin Research Center, Louis-H. Lafontaine Hospital

Academic profile

MD, Université de Montréal (1968)
Psychiatry Residency, McGill University (1972)
M.Sc. in pharmacology, Université de Montréal (1974)

Research interests

His main interests are linked to the treatment of schizophrenic and bipolar psychosis. His work on these two psychiatric conditions has significantly contributed to identify, prevent and treat the extrapyramidal symptoms induced by the neuroleptics. His research has also helped to develop new therapeutic approaches. He contributed to the introduction of anticonvulsants (such as clonazepam or tryptophan) as an adjuvant treatment and to the use of prophylactric in the case of bipolar psychosis.

Dr. Chouinard has also contributed to the introduction of atypical neuroleptics. His work has facilitated the treatment of schizophrenia and bipolar disorder by providing a better comprehension of the neurophysiology of these conditions.

Publications récentes

Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., et al. (2009). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. International Journal of Neuropsychopharmacology, Aug 20, Epub ahead of print.Pubmed 

Corruble, E., Chouinard, V., Letierce, A., Gorwood, P., & Chouinard, G. (2009). Is DSM-IV bereavement exclusion for major depressive episode relevant to severity and pattern of symptoms? A case-control, cross-sectional study. Journal of Clinical Psychiatry, 70(8), 1091-1097. –  Pubmed

Peretti, C.S., Ferreri, F., Blanchard, F., Bakchine, S., Peretti, C., Dobrescum, A., Chouinard, V.A, Chouinard, G (2008). "Normal and Pathological Aging of Attention in Presymptomatic Huntington’s, Huntington’s and Alzheimer’s disease, and Non-Demented Elderly Subjects" Psychother and Psychosom 77(3): 139-146 Epub.

Chouinard, G., Chouinard, V.A. (2008)"Atypical Antipsychotics: CATIE study, Drug-Induced Movement Disorder (DIMD), DIMD Iatrogenic Psychiatric-like Symptoms, Supersensitivity/Rebound Psychosis and Withdrawal Discontinuation Syndrome" Psychother and Psychosom 77(2): 69-77.

Chouinard, G. (2006) "Inter-Relationships Between Psychiatric Symptoms and Drug-Induced Movement Disorder (DIMD): Part 2: Heinz Lehmann Award 2004". J Psychiatry Neurosci 31(3) :177-180.

Chouinard, G. (2006) "The Search for New Off Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs: Part 1: Heinz Lehmann Award 2004". J Psychiatry Neurosci 31(3) :168-176.

Chouinard, G. (2005) "Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS)". Schizophrenia Research 76:247-265.

Gharabawi, G.M., Bossie, C.A., Lasser, R.A., Turkoz, I., Rodriguez, S., Chouinard, G. (2005) "Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-Scale Comparison in Assessing Tardive Dyskinesia". Schizophrenia Research 77:119-128.

Margolese, H, Chouinard, G, Kolivakis, T, Beauclair, L, Miller, R, Annable, L. (2005) "Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics (Part 2): Incidence and Management Strategies in Patients with Schizophrenia". Can J Psychiatry 50:541-547.